L-folinic acid

DRUG3 trials

Sponsors

The Christie NHS Foundation Trust, Institut Cancerologie de l'Ouest, National Cancer Institute, Naples

Conditions

Ampullary CancerBiliary Tract CancerCholangiocarcinomaColorectal Cancer Stage IVDigestive CancerGallbladder Cancer

Phase 1

Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers

TerminatedNCT03294252

Institut Cancerologie de l'OuestDigestive Cancer

Start: 2017-05-24End: 2021-10-01Updated: 2022-04-25

Phase 3

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers

CompletedNCT01926236

The Christie NHS Foundation TrustAmpullary Cancer, Biliary Tract Cancer, Cholangiocarcinoma +1

Start: 2014-02-28End: 2019-01-31Updated: 2020-01-28

Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer

RecruitingNCT06509126

National Cancer Institute, NaplesColorectal Cancer Stage IV

Start: 2024-06-12End: 2028-06-30Target: 500Updated: 2024-07-19

Related Papers

PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX): An open label, non-comparative phase 1/2 dose escalation and expansion trial.

Journal of Clinical Oncology2024-06-01

Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA.

2023-07-2720 citations

Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 trial.

Journal of Clinical Oncology2023-01-245 citations

Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design

Pleura and Peritoneum2022-06-2010 citations

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.

2021-03-30533 citations

Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.

2020-11-1674 citations

A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers.

2020-10-0838 citations

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

Journal for ImmunoTherapy of Cancer2020-05-01140 citations

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

Journal of Clinical Oncology2019-05-20226 citations

Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal).

Journal of Clinical Oncology2019-05-202 citations

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as an outpatient procedure

Pleura and Peritoneum2018-11-2535 citations

Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rationale and design

Pleura and Peritoneum2018-09-0136 citations